INR Above or Below the Therapeutic Range
Increased INR, Coumadin over-dosage; low INR, inadequate Coumadin dosage
Clinical conditions that increase Coumadin effect and elevate INR include:
Low vitamin K intake
Poor nutritional state
Congestive heart failure
Connective tissue diseases
Conditions known to decrease Coumadin effect and decrease INR include:
High vitamin K intake
Many drugs are known to increase warfarin effect and elevate INR:
Effects may be dose-dependent & may not occur in all pts receiving Coumadin & the drug mentioned.
Drugs in this category include carbenicillin, allopurinol, erythromycin, indomethacin, ibuprofen, fluconazole, fenoprofen, isoniazid, ketoconazole, naproxen, metronidazole, phenylbutazone, moxalactam, cephalosporins, trimethoprim-sulfa (Bactrim), amiodarone, quinidine, cimetidine, clofibrate, lovastatin, omeprazole, phenytoin, tamoxifen, thyroxine, quinolones, rofecoxib, celecoxib.Drugs that can decrease warfarin effect & lower INR in some pts include antacids, antihistamines, barbiturates, rifampin, sucralfate, trazodone, carbamazepine, cholestyramine, griseofulvin, haloperidol, oral contraceptives, penicillin, dicloxacillin, and nafcillin.
Suggested Additional Lab Testing
Most important: INR value on a daily basis until patient shows a consistent value within therapeutic range at least 2 or 3 times.
Monitoring is then less frequent but at least 1 times per month.
Lab tests may be helpful in uncovering other conditions, such as liver disease, which lowers the level of coagulation factors and makes therapeutic anticoagulation difficult. Pharmacogenomics testing is a consideration, either before initiation of warfarin, shortly after initiation, or for patients with apparent hypersensitivity to warfarin.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- Combined Digital Screening Best for Detecting Breast Cancers
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Seeking Reliable Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- The Efficacy and Tolerance of High Pressure Oxygen Combined With Chemotherapy in Postoperative Patients With Advanced Gastric Cancer
- Hepatocellular Cancer Pain: Impact and Management Challenges
- Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|